Veru Inc. Signs Material Definitive Agreement
Ticker: VERU · Form: 8-K · Filed: Sep 20, 2024 · CIK: 863894
Sentiment: neutral
Topics: material-agreement, corporate-news
TL;DR
Veru Inc. just signed a big deal, details to come.
AI Summary
Veru Inc. entered into a material definitive agreement on September 19, 2024. The company, previously known as The Female Health Co. and Wisconsin Pharmacal Company Inc., is incorporated in Wisconsin and headquartered in Miami, Florida.
Why It Matters
This filing indicates a significant new contract or partnership for Veru Inc., which could impact its future business operations and financial performance.
Risk Assessment
Risk Level: medium — The nature of the material definitive agreement is not disclosed, leaving investors uncertain about its terms and potential impact.
Key Players & Entities
- Veru Inc. (company) — Registrant
- The Female Health Co. (company) — Former company name
- Wisconsin Pharmacal Company Inc (company) — Former company name
- September 19, 2024 (date) — Date of earliest event reported
FAQ
What is the nature of the material definitive agreement Veru Inc. entered into?
The filing does not specify the details of the material definitive agreement.
When was the material definitive agreement entered into?
The material definitive agreement was entered into on September 19, 2024.
What is Veru Inc.'s principal executive office address?
Veru Inc.'s principal executive office is located at 2916 N. Miami Avenue, Suite 1000, Miami, Florida 33127.
What were Veru Inc.'s previous company names?
Veru Inc. was formerly known as The Female Health Co. and Wisconsin Pharmacal Company Inc.
What is Veru Inc.'s fiscal year end?
Veru Inc.'s fiscal year ends on September 30.
Filing Stats: 1,244 words · 5 min read · ~4 pages · Grade level 15.5 · Accepted 2024-09-20 16:11:57
Key Financial Figures
- $0.01 — ange on which registered Common Stock, $0.01 par value per share VERU NASDAQ Cap
- $5,000,000 — missory Note in the principal amount of $5,000,000 due on April 19, 2024 (the "April 2024
- $3,500,000 — Note will be reduced from $5,000,000 to $3,500,000. 2 There can be no assurance as to
Filing Documents
- d881365d8k.htm (8-K) — 33KB
- d881365dex101.htm (EX-10.1) — 40KB
- 0001193125-24-222901.txt ( ) — 206KB
- veru-20240919.xsd (EX-101.SCH) — 3KB
- veru-20240919_lab.xml (EX-101.LAB) — 18KB
- veru-20240919_pre.xml (EX-101.PRE) — 11KB
- d881365d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits . Exhibit No. Document 10.1 Amended and Restated Forbearance Agreement and Amendment to September 2024 Note, dated as of September 19, 2024, between Veru Inc. and Onconetix, Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 3
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 20, 2024 VERU INC. By: /s/ Michele Greco Michele Greco Chief Financial Officer and Chief Administrative Officer 4